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Commentary
Human and experimental data show that nutritional
supplementation with a specific mixture of essential amino (EAA)
improves both mitochondrial function and biogenesis and reduces
either ROS formation or apoptotic drive in myocytes [1-2].
Supplementation with EAA is also effective in humans when tested in
patients with cardiac dysfunction [3]. Doxorubicin (Doxo), an
effective cancer chemotherapy agent, causes severe cardio-toxicity due
to mitochondria damage, production of reactive oxygen species (ROS)
and cell apoptosis with myofibrillar disarrangement, which in turn
induces chronic heart failure. Pathogenesis of toxicity, as reported by
Zhang et al. [4] is connected to the binding of Doxo to topoisomerase-
IIb , which triggers a complex cascade of events, altering the DNA
response and apoptosis pathways and triggering a marked alteration in
the transcriptome, that selectively affects oxidative phosphorylation
and mitochondrial biogenesis in cardiomyocytes. As a result, Doxo-
induced cardiotoxicity limits optimal drug-dose use, reducing its
potential therapeutic effects in cancer patients [5].
Consequently, we hypothesized that supplementation with EAA
would blunt Doxo cardio-toxicity, but we also tested if this would
happen without interfering with the Doxo therapeutic effects on
cancer cells. We used C57BL/6 mice fed on a normal diet and i.p.
injected with a single saline or Doxo-HCl (15 mg/kg, from Sigma-
Aldrich) injection to induce cardiomyopathy [6], with or without oral
supplementation of EAA (1.5 g/kg). After 14 days, the heart was
collected and morphologically evaluated by optical and electron
microscopy. In addition, to test whether EAA supplementation
negatively interferes with the Doxo anticancer action, we treated
different cancer cell lines (3 × 105 cells/well in DMEM medium of
HCT116 colon carcinoma; MCF7 mammary gland carcinoma; M14
melanoma), with Doxo (0.7 microg/ml) and with or without EAA (1%
w/v). Untreated cancer cell lines (cultured in DMEM only) were used
as controls. The osmolarity of the culture medium was the same for all
groups. After 24 hours the cells were counted with the Trypan blue dye
exclusion assay to distinguish live from dead cells.
The in vivo experiments showed that Doxo significantly lowered
body weight (22.59 ± 1.33 g vs 30.12 ± 1.4 g. p<0.05) and heart weight
(0.12 ± 0.01 g vs 0.17 ± 0.01 g. p<0.05) compared to the control group.
Furthermore, Doxo induced morphological alteration of
cardiomyocytes with giant and irregularly shaped nuclei with
condensed chromatin (Figure 1a A-C). In addition, Doxo impaired
cellular distribution, morphology and the number of mitochondria (24
± 2.8 vs 31.62 ± 5.5 Nmit/100µ2. p<0.05). Interestingly, EAA
supplementation of Doxo-treated animals protected normal heart
weight (0.16 ± 0.01 g vs 0.12 ± 0.01 g. p<0.05) and preserved
cardiomyocytes architecture, mitochondrial morphology and number
(28 ± 2.8 vs 24 ± 2.8 Nmit/100µ2. p<0.05) (Figure 1a D-F).
Figure 1a: (A-C) Eosin/Hematoxilin staining (Scale bar 10μ), and
(D-F) electron microscopy pictures (Scale bar 1.5μ) according to
the groups EAA, Doxo, EAA+Doxo. The white arrow indicate a
dense body (cellular debris). N = nucleus.
The in vivo findings were partially surprising because previous
studies had shown that EAA nutritional supplementation stimulates
mitochondrial biogenesis and endogenous defences against ROS. The
consequences were: reduced cell damage, improved cellular energy
production and preserved muscular structure, which finally increased
life span of aged animals [1].
As expected, the in vitro experiments confirmed the Doxo action on
cancer cells, causing about 60% of cell death vs untreated (control) cell
after 24h. On the contrary and surprisingly, EAA administration with
or without Doxo, increased cancer cell mortality (Figure 1b).
Interestingly, EAA alone increased the apoptotic markers: cleaved-
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Caspase 3 (0.75 fold) and Bax (2.7 fold) in isolated cancer cells (Figure
1c).
Figure 1b: Mortality after 24h of cancer cells lines untreated (C) and
treated with EAA, Doxo and EAA+Doxo. Results are expressed as
% increase compared to time zero (n° of plated cells = 3 × 105).
SNK-test *p<0.05 vs C and °p<0.05 vs EAA.
Figure 1c: Relative fold increase of apoptotic markers in HCT116
cell line untreated and treated with EAA.
We hypothesize that cancer cells are most dependent on the
environmental availability of non-EAA for cell signalling, protein
synthesis and cell proliferation. Therefore, we suggest that a “positive
imbalance” between EAA and non-EAA may alter cancer cells
environment and possibly trigger a signalling cascade which in turn
induces a series of events incompatible with proliferation and survival
of cancer cells. Further studies are in progress to clarify the
mechanisms possibly connected to these intriguing findings.
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